Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang, 110004, China.
Department of Pathophysiology, China Medical University, Taichung, China.
Arch Gynecol Obstet. 2023 Oct;308(4):1369-1378. doi: 10.1007/s00404-023-07175-6. Epub 2023 Aug 8.
Intrauterine adhesion (IUAs) in women is a debatable topic and there is no clear consensus in its management and treatment strategies. Previous treatment measures have limitations which necessitates to consider effective measures for prevention of recurrence of IUAs. Hence, the aim of this study to explore the efficacy and safety of intrauterine infusion of autologous platelet gel (APG) and medical chitosan in preventing recurrence of IUAs in females after transcervical resection of adhesion (TCRA).
A prospective, randomized controlled trial was conducted among 80 patients presented with moderate to severe IUAs. Patients were randomized into two groups, APG group (n = 40) and medical chitosan group (n = 40). All patients were injected with either APG or medical chitosan after TCRA.
The postoperative recurrence rate of adhesions in APG group was significantly lower than those in medical chitosan group (21% vs 49%). The median AFS score during the second-look hysteroscopy was significantly lower in APG group than in medical chitosan group (P = 0.008). The median AFS score reduction after TCRA surgery was significantly higher in APG group than in medical chitosan group (median, 95% CI 7.000, 6.0 to 8.3 vs. 6.000, 5.0 to 7.0, P = 0.004). Subgroup analysis of platelet concentration (1000 as cut-off value) into high- and low-dose subgroups reported no significant correlation existed between APG and baseline characteristics, recurrence rate and postoperative AFS reduction score except for previous intrauterine operation (P < 0.05).
Thus, after TCRA, intrauterine injections of APG provides better efficacy and safety compared with intrauterine injections of medical chitosan in preventing recurrence of intrauterine adhesions.
宫腔粘连(IUAs)在女性中是一个有争议的话题,其管理和治疗策略尚无明确共识。以前的治疗措施存在局限性,因此需要考虑预防 IUAs 复发的有效措施。因此,本研究旨在探讨宫腔内注射自体血小板凝胶(APG)和医用壳聚糖预防经宫颈粘连切除术(TCRA)后女性 IUAs 复发的疗效和安全性。
对 80 例中重度 IUAs 患者进行前瞻性、随机对照试验。患者随机分为 APG 组(n=40)和医用壳聚糖组(n=40)。所有患者在 TCRA 后均注射 APG 或医用壳聚糖。
APG 组术后粘连复发率明显低于医用壳聚糖组(21%比 49%)。第二次宫腔镜检查时 AFS 评分中位数在 APG 组明显低于医用壳聚糖组(P=0.008)。TCRA 手术后 AFS 评分降低中位数在 APG 组明显高于医用壳聚糖组(中位数,95%CI7.000,6.0 至 8.3 比 6.000,5.0 至 7.0,P=0.004)。将血小板浓度(以 1000 为界值)分为高、低剂量亚组进行亚组分析,除既往宫腔内操作外(P<0.05),APG 与基线特征、复发率和术后 AFS 降低评分之间无明显相关性。
因此,与宫腔内注射医用壳聚糖相比,TCRA 后宫腔内注射 APG 可更好地预防宫腔粘连复发。